The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies

Overview

The muscular dystrophies (MD) are a group of more than 30 neuromuscular disorders that are characterized by progressive skeletal muscle weakness, defects in muscle proteins and the death of muscle cells and tissue. This study will investigate the use of far infrared radiation for managing muscular dystrophies.

Full Title of Study: “Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2010

Detailed Description

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly cure these neuromuscular disorders.

Interventions

  • Radiation: Far Infrared Radiation
    • Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.

Arms, Groups and Cohorts

  • Experimental: 1
    • Radiation: Far Infrared Radiation (5μm to 20μm wavelength)

Clinical Trial Outcome Measures

Primary Measures

  • Management and Cure of muscular dystrophies
    • Time Frame: 2 Years

Secondary Measures

  • Rehabilitation of people with muscular dystrophies
    • Time Frame: 2 Years

Participating in This Clinical Trial

Inclusion Criteria

  • Persons with muscular dystrophies Exclusion Criteria:

  • None

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • GAAD Medical Research Institute Inc.
  • Provider of Information About this Clinical Study
    • Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
  • Overall Official(s)
    • Ken Nedd, M.D., Principal Investigator, GAAD Medical Research Institute Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.